Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma

Table 2

Multivariate logistic regression analysis.

Group	Factor	Odds ratio	95% confidence interval	p value
All patients	Ann Arbor staging (III and IV)	2.09	0.84–5.24	0.118
	Bone marrow infiltration	2.03	0.56–7.43	0.284
	Splenomegaly	1.81	0.44–7.50	0.415
	Indolent lymphoma	0.87	0.29–2.61	0.800
	Glucocorticoid use before rituximab infusion	0.17	0.05–0.59	0.005
Patients without glucocorticoid use before rituximab infusion	Ann Arbor staging (III and IV)	1.94	0.73–5.18	0.185
	Bone marrow infiltration	4.00	1.02–15.79	0.047